Minimally Invasive Versus Open Liver Resection for Patients With Colorectal Cancer Liver Metastases
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03895723 |
Recruitment Status : Unknown
Verified March 2019 by Xu jianmin, Fudan University.
Recruitment status was: Recruiting
First Posted : March 29, 2019
Last Update Posted : March 29, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Colorectal Liver Metastasis | Procedure: laparoscopic and robotic liver resection Procedure: open surgery | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 220 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Intervention Model Description: | Arm A: minimally invasive surgery Arm B: open |
Masking: | Single (Outcomes Assessor) |
Masking Description: | The assessor was masking for patients treatment arms |
Primary Purpose: | Treatment |
Official Title: | Minimally Invasive(Laparoscopic and Robotic) Versus Open Liver Resection for Patients With Colorectal Cancer Liver Metastases |
Actual Study Start Date : | March 1, 2019 |
Estimated Primary Completion Date : | April 1, 2021 |
Estimated Study Completion Date : | April 1, 2024 |
Arm | Intervention/treatment |
---|---|
Experimental: Minimally Invasive surgery
the intevention of Minimally Invasive procedure contains laparoscopic and robotic liver resection
|
Procedure: laparoscopic and robotic liver resection
laparoscopic and robotic procedure for liver resection |
Open surgery
the open surgery means traditional open surgery for liver resection
|
Procedure: open surgery
using open surgery procedure for liver resection |
- disease-free survival (DFS) [ Time Frame: 3 years disease-free survival ]DFS was calculated from the date of liver resection to the date of death or recurrence or new tumors developing
- Overall survival (OS) [ Time Frame: 5 years overall survival ]OS was calculated from the date of liver resection to the date of death with any reason
- Sugical complications [ Time Frame: 1 months after sugery ]According to Claivein-Dindo surgical complication system to calculate the perioperative complications related to surgery
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 75 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- patients were diagnosed with colorectal cancer liver metastases
- without extra-hepatic liver metastases
- age were within 18-75 yeas
- the numbers of metastases more than 3
- the maximal tumor size of liver metastases more than 10 cm
Exclusion Criteria:
- liver metastases were unresectable.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03895723
China, Shanghai | |
Wenju Chang | Recruiting |
Shanghai, Shanghai, China, 200032 | |
Contact: Wenju Chang, MD +8613764476150 chang_erich@hotmail.com |
Responsible Party: | Xu jianmin, Director of colorectal cancer center, Fudan University |
ClinicalTrials.gov Identifier: | NCT03895723 |
Other Study ID Numbers: |
RSRCLM-02 |
First Posted: | March 29, 2019 Key Record Dates |
Last Update Posted: | March 29, 2019 |
Last Verified: | March 2019 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Colorectal liver metastasis Minimally invasive surgery Robotic surgery Laparoscopic surgery |
Neoplasm Metastasis Liver Neoplasms Digestive System Neoplasms Neoplasms by Site Neoplasms |
Digestive System Diseases Neoplastic Processes Pathologic Processes Liver Diseases |